Bleeding related to disturbed fibrinolysis

K. Kolev, Colin Longstaff

Research output: Contribution to journalReview article

25 Citations (Scopus)

Abstract

The components and reactions of the fibrinolysis system are well understood. The pathway has fewer reactants and interactions than coagulation, but the generation of a complete quantitative model is complicated by the need to work at the solid-liquid interface of fibrin. Diagnostic tools to detect disease states due to malfunctions in the fibrinolysis pathway are also not so well developed as is the case with coagulation. However, there are clearly a number of inherited or acquired pathologies where hyperfibrinolysis is a serious, potentially life-threatening problem and a number of antifibrinolytc drugs are available to treat hyperfibrinolysis. These topics will be covered in the following review.

Original languageEnglish
Pages (from-to)12-23
Number of pages12
JournalBritish Journal of Haematology
Volume175
Issue number1
DOIs
Publication statusPublished - Oct 1 2016

Fingerprint

Fibrinolysis
Hemorrhage
Fibrin
Pathology
Pharmaceutical Preparations

Keywords

  • acute promyelocytic leukaemia
  • antiplasmin
  • bleeding disorders
  • fibrinolysis
  • plasminogen activator inhibitor type 1

ASJC Scopus subject areas

  • Hematology

Cite this

Bleeding related to disturbed fibrinolysis. / Kolev, K.; Longstaff, Colin.

In: British Journal of Haematology, Vol. 175, No. 1, 01.10.2016, p. 12-23.

Research output: Contribution to journalReview article

Kolev, K. ; Longstaff, Colin. / Bleeding related to disturbed fibrinolysis. In: British Journal of Haematology. 2016 ; Vol. 175, No. 1. pp. 12-23.
@article{b1494fd8630542e89c56862dd0c6d6cf,
title = "Bleeding related to disturbed fibrinolysis",
abstract = "The components and reactions of the fibrinolysis system are well understood. The pathway has fewer reactants and interactions than coagulation, but the generation of a complete quantitative model is complicated by the need to work at the solid-liquid interface of fibrin. Diagnostic tools to detect disease states due to malfunctions in the fibrinolysis pathway are also not so well developed as is the case with coagulation. However, there are clearly a number of inherited or acquired pathologies where hyperfibrinolysis is a serious, potentially life-threatening problem and a number of antifibrinolytc drugs are available to treat hyperfibrinolysis. These topics will be covered in the following review.",
keywords = "acute promyelocytic leukaemia, antiplasmin, bleeding disorders, fibrinolysis, plasminogen activator inhibitor type 1",
author = "K. Kolev and Colin Longstaff",
year = "2016",
month = "10",
day = "1",
doi = "10.1111/bjh.14255",
language = "English",
volume = "175",
pages = "12--23",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Bleeding related to disturbed fibrinolysis

AU - Kolev, K.

AU - Longstaff, Colin

PY - 2016/10/1

Y1 - 2016/10/1

N2 - The components and reactions of the fibrinolysis system are well understood. The pathway has fewer reactants and interactions than coagulation, but the generation of a complete quantitative model is complicated by the need to work at the solid-liquid interface of fibrin. Diagnostic tools to detect disease states due to malfunctions in the fibrinolysis pathway are also not so well developed as is the case with coagulation. However, there are clearly a number of inherited or acquired pathologies where hyperfibrinolysis is a serious, potentially life-threatening problem and a number of antifibrinolytc drugs are available to treat hyperfibrinolysis. These topics will be covered in the following review.

AB - The components and reactions of the fibrinolysis system are well understood. The pathway has fewer reactants and interactions than coagulation, but the generation of a complete quantitative model is complicated by the need to work at the solid-liquid interface of fibrin. Diagnostic tools to detect disease states due to malfunctions in the fibrinolysis pathway are also not so well developed as is the case with coagulation. However, there are clearly a number of inherited or acquired pathologies where hyperfibrinolysis is a serious, potentially life-threatening problem and a number of antifibrinolytc drugs are available to treat hyperfibrinolysis. These topics will be covered in the following review.

KW - acute promyelocytic leukaemia

KW - antiplasmin

KW - bleeding disorders

KW - fibrinolysis

KW - plasminogen activator inhibitor type 1

UR - http://www.scopus.com/inward/record.url?scp=84988515809&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988515809&partnerID=8YFLogxK

U2 - 10.1111/bjh.14255

DO - 10.1111/bjh.14255

M3 - Review article

C2 - 27477022

AN - SCOPUS:84988515809

VL - 175

SP - 12

EP - 23

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -